Current Studies — Welcome to Infinity Clinical Research

Current Studies

The facts about participating in clinical research and our ongoing studies:

First and foremost your safety is our top priority. Participating in clinical research gives you access to the latest medical and scientific innovations in medicine as well as compensates the participant(s) for time and travel. Most importantly, you are advancing medical science by contributing to the development of vital new medicines and paving the way for these new medicines to reach the market.

Please let us know if you are interested in participating in a research study. Study participants receive medical care, lab tests, and study medication at no cost, and are compensated for their participation. Transportation can be provided.

For more information, please call: 954-366-0277.



Study Coordinator: Joel Espinoza
954-981-3850 x302 / jespinoza@infinityclinicalresearch.com

EPOCH:   Alzheimer’s Disease
A two-year study to evaluate a novel new oral drug as a potential disease-modifying therapy in patients 55 to 85 years old with mild to moderate Alzheimer’s Disease.  This is a VERY EXCITING new medicine!  This medicine may prevent the formation of Beta Amyloid plaque…which is a toxic build-up of plaque in the brain that causes memory problems and loss of activities of daily living.

019:   Memory Loss
A two year study with the same medicine as in EPOCH for patients experiencing memory loss for a year.  This study is a critical step in early detection and treatment for those who may go on to develop Alzheimer’s Disease.

MARGUERITE ROAD:   Alzheimer’s Disease
A two year study with a disease modifying treatment given by subcutaneous injection in patients 50 to 90 years old with mild Alzheimer’s Disease.

EXPEDITION 3:   Alzheimer’s Disease
A 2 year study to evaluate a disease modifying treatment given monthly by intravenous infusion on the effect of passive immunization on the progression of mild Alzheimer’s Disease in patients who are 55 to 90 years old.

012:   Alzheimer’s Disease
 A 6-month study evaluating the effectiveness of a new medicine for those patients between 55 and 85 years old and already on a stable dose of Aricept for treating the symptoms of mild to moderate Alzheimer’s Disease.

REFLEX:   Post-Stroke Lower Limb Spasticity
 A 12-week study evaluating Botox in patients 18 to 85 years old with post-stroke lower limb spasticity.  Patients can continue in the study for up to 3 additional treatment cycles for those who continue to be eligible.

REMIND:   Brain Tumor
A 6-week study evaluating adult patients with known or highly suspected primary intracranial tumors detected by previous CT or MRI examination who are scheduled to undergo a routine contrast-enhanced MRI.  The contrast agent in this study is already FDA approved!  There are two MRI’s that are provided to the patient at no cost.


Lead Study Coordinator: Lucy Vargas
954-981-4491 / lvargas@infinityclinicalresearch.com

SUMMIT:  Moderate COPD with High Cardiovascular Risk
A three-year clinical outcome study to compare the effect of a combination Inhalation powder in patients who are 40 to 80 years old, current or former smokers, with moderate COPD and history of or at increased risk for cardiovascular disease.   This is a LANDMARK clinical trial involving 16,000 patients globally!

ASCENT COPD:   Moderate to Severe COPD with High Cardiovascular Risk
A three year post-marketing study to evaluate the effect of aclidinium bromide (Tudorza Pressair) on long-term cardiovascular safety and COPD attacks in patients 40 years old or older who are current or former smokers, with moderate to very severe COPD and a history of cardiovascular or cerebrovascular disease and/or significant cardiovascular risk.  This medicine is already FDA approved!

iiMPRESS:   Diabetes with Obstructive Pulmonary Disease
A 1-year study to evaluate the safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic patients with obstructive pulmonary disease (asthma or chronic obstructive pulmonary disease)


Study Coordinator: Becky Nembhard
954-965-4900 x173 / rnembhard@infinityclinicalresearch.com

CADENCE 215:  New Onset Event of Paroxysmal or Persistent Atrial Fibrillation
A one-month study to evaluate a very exciting new medicine which acts as a chemical cardioversion agent and can be a first treatment option for those experiencing a new onset event of AFib.

CANTOS:  Cardiovascular Risk Reduction in Patients Following a Heart Attack
A five-year study to evaluate the benefit of quarterly doses of a novel new medicine given by  subcutaneous injection in stable post-heart attack patients who are at least 18 years old receiving standard of care therapy and have an elevated inflammatory burden as documented by recent labs.

DECLARE: Cardiovascular Risk in Type II Diabetics
A six-year study to evaluate whether treatment with a novel first-in-class medicine reduces major adverse cardiac events in patients who are at least 40 years old with type 2 diabetes and with either known cardiovascular disease or at least two risk factors for cardiovascular disease in addition to diabetes who are considered at high risk for a cardiovascular event (heart attack).

CARMELINA: Cardiovascular Risk and Renal Outcomes in Type II Diabetics
A four-year post-marketing cardiovascular safety and renal outcomes study with an FDA approved medicine Tradjenta (lingaliptin), in patients who are 18 years old, have type 2 diabetes on a stable dose of antidiabetic medicine, and are at high risk for cardiovascular events.

ODYSSEY: Recent Acute Coronary Syndrome with Obstructive Coronary Disease
A five-year study comparing a novel new class of drug on the occurrence of cardiovascular events in patients at least 40 years old who have experienced an acute coronary syndrome (ACS) event (heart attack) and despite intensive lipid modifying or statin therapy, are not adequately controlled.

WARFARIN: Anticoagulation Therapy
This is a three-month study designed to assess if incorporating genotype testing results of two specific gene variants into a warfarin dosing protocol can change the number of adverse events related to warfarin in subjects 65 years old or older and beginning anti-coagulation therapy.

ePAD: Peripheral Arterial Disease
A six-month study in patients at least 18 years old who have undergone successful angioplasty, evaluating a novel new medicine or clopidogrel (Plavix) and aspirin to maintain patency in subjects with peripheral arterial disease following intervention.


Lead Study Coordinator: Irys Caristo
954-738-1686 / icaristo@infinityclinicalresearch.com

PREFERMS:  Relapsing-Remitting MS
A one- year study to evaluate FDA approved oral Fingolimod (Gilenya) vs. approved 1st-line disease modifying therapies in adults at least 18 years old with relapsing-remitting multiple sclerosis who are in early stages of treatment.

ASSESS:  Relapsing-Remitting MS
A one-year study to compare efficacy and safety of 2 doses of oral Fingolimod (Gilenya) to Copaxone in adults at least 18 years old with relapsing-remitting multiple sclerosis.

TERI-PRO: Relapsing MS
A one-year, real-life clinical-setting study to describe effectiveness, tolerability and convenience of an oral FDA approved medicine, teriflunomide (Aubagio) using Patient Reported Outcomes in Relapsing forms of multiple sclerosis

PATHWAY-1: Relapsing-Remitting MS
A one-year study of a new medicine – plovamer acetate – as a weekly subcutaneous injection compared with Copaxone (glatiramer acetate) daily injections in patients with relapsing-remitting multiple sclerosis.

FOCUS-1: Relapsing-Remitting MS
A two-year study comparing a new oral medicine to Avonex 30 μg as a weekly subcutaneous injection in patients 18 to 55 years old with relapsing-remitting multiple sclerosis.

FOCUS-2: Relapsing MS
A two-year study comparing a new oral medicine to Avonex 30 μg as a weekly subcutaneous injection in patients 18 to 55 years old with relapsing multiple sclerosis.

EXPAND:  Secondary Progressive MS
A four-year study evaluating a new oral medicine in patients 18 to 60 years old with secondary progressive multiple sclerosis.